GlassScriptPhysician profile
Renee Hernandez
NPI 1588189922
$8,707.71
in general payments reported to CMS, 2019-2025
31 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,583 · 2022: $1,598 · 2023: $2,344 · 2024: $1,318 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,122 · Travel and Lodging: $320 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,122.15 |
| Travel and Lodging | $320.05 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,224.88 | 2021-2025 | |
| Abbott Laboratories | $1,373.13 | 2021-2025 | Coroflow, Jeti Peripheral Catheter, Jeti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,011.03 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Enterra Medical, INC. | $575.83 | 2023-2024 | |
| Janssen Biotech, INC. | $466.82 | 2021-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $370.44 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.82 | 2021-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $290.42 | 2021-2025 | Injectafer |
| Lilly USA, LLC | $209.89 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $200.91 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $173.90 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $155.48 | 2021-2023 | |
| Madrigal Pharmaceuticals | $150.24 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $143.70 | 2023 | Cre Pro |
| Ardelyx, INC. | $126.04 | 2023-2025 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $100.62 | 2024 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $88.72 | 2024-2025 | Iqirvo |
| Pfizer INC. | $87.88 | 2021-2025 | |
| Genzyme Corporation | $83.34 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $69.82 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $65.06 | 2021-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $63.58 | 2021-2023 | Dificid |
| Axonics, INC. | $56.33 | 2021-2022 | |
| Gilead Sciences, INC. | $55.15 | 2021 | |
| Pharmacosmos Therapeutics INC. | $49.30 | 2021 | |
| Redhill Biopharma INC. | $47.34 | 2022-2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $42.04 | 2021-2023 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $24.48 | 2024 | Terlivaz |
| Novo Nordisk INC | $16.32 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $14.28 | 2022 | |
| Ethicon US, LLC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.